Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Icon Advisers Inc. Co.
Icon Advisers Inc. Co. raised its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 36,400 shares of the biopharmaceutical company’s stock after purchasing an additional 2,400 shares during the quarter. Icon Advisers Inc. Co.’s holdings in Alexion Pharmaceuticals were worth $4,353,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in ALXN. Jennison Associates LLC grew its position in shares of Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Alexion Pharmaceuticals by 4,509.0% in the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Factory Mutual Insurance Co. grew its position in shares of Alexion Pharmaceuticals by 104.5% in the fourth quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock valued at $42,873,000 after purchasing an additional 183,200 shares during the last quarter. Creative Planning grew its position in shares of Alexion Pharmaceuticals by 72.2% in the fourth quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock valued at $3,321,000 after purchasing an additional 11,642 shares during the last quarter. Finally, USA Financial Portformulas Corp acquired a new position in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $3,632,000. Hedge funds and other institutional investors own 94.04% of the company’s stock.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $108.60 on Friday. The stock has a market capitalization of $24,045.78, a P/E ratio of 21.39, a P/E/G ratio of 0.91 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.51 and a current ratio of 3.10.
In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 655 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ludwig Hantson sold 13,245 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $1,540,525.95. Following the sale, the chief executive officer now owns 131,425 shares of the company’s stock, valued at $15,286,041.75. The disclosure for this sale can be found here. Insiders have sold 28,930 shares of company stock worth $3,378,199 in the last three months. 4.35% of the stock is currently owned by company insiders.
Several equities analysts have recently commented on the company. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Leerink Swann decreased their target price on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday. Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 target price (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada upped their target price on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $153.14.
ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2018/02/10/alexion-pharmaceuticals-inc-alxn-shares-bought-by-icon-advisers-inc-co.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.